{"bill": {"#text": "\n  ", "form": {"current-chamber": {"#tail": "\n    ", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n", "congress": {"#tail": "\n    ", "#text": "113th CONGRESS"}, "#tail": "\n  ", "legis-num": {"#tail": "\n    ", "#text": "H. R. 3709"}, "official-title": {"#tail": "\n  ", "#text": "To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes."}, "session": {"#tail": "\n    ", "#text": "1st Session"}, "distribution-code": {"#tail": "\n    ", "@display": "yes", "#text": "I"}, "action": {"action-date": {"#tail": "\n      ", "@date": "20131211", "#text": "December 11, 2013"}, "#tail": "\n    ", "action-desc": {"#tail": "\n    ", "#text": "\n        ", "committee-name": [{"#tail": ", and in addition to the Committee on the ", "@committee-id": "HIF00", "#text": "Committee on Energy and Commerce"}, {"#tail": ", for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned", "@committee-id": "HJU00", "#text": "Judiciary"}], "sponsor": {"#tail": " (for himself, ", "#text": "Mr. Rush", "@name-id": "R000515"}, "cosponsor": [{"#tail": ", and ", "#text": "Mr. Van Hollen", "@name-id": "V000128"}, {"#tail": ") introduced the following bill; which was referred to the ", "#text": "Mr. Waxman", "@name-id": "W000215"}]}, "#text": "\n      "}, "legis-type": {"#tail": "\n    ", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-House", "@bill-type": "olc", "@dms-id": "H3596AE7F0A6542DDB8CA7F8B658C21CD", "@public-private": "public", "legis-body": {"#tail": "\n", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n    ", "quote": {"short-title": {"#tail": "\n        ", "#text": "Protecting Consumer Access to Generic Drugs Act of 2013"}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "@display-inline": "no-display-inline", "#text": "\n      ", "@id": "HC9F95EF7514049A6B9F193EDA002F47A"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Unfair and deceptive acts and practices related to new drug applications"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n        ", "#text": "It shall be unlawful for any person to directly or indirectly be a party to any agreement resolving or settling a patent infringement claim in which\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Conduct prohibited"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n        ", "#text": "an ANDA filer receives anything of value; and"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "HE796B47A47E848EFBE8B9756AD291A1C", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n        ", "#text": "the ANDA filer agrees not to research, develop, manufacture, market, or sell, for any period of time, the drug that is to be manufactured under the ANDA involved and is the subject of the patent infringement claim."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "H46E4F98782DE4D7D832F801F69597399", "#text": "\n          "}], "#text": "\n        ", "@id": "H8A7BF423D6D041EB881B3C9EEE973A15"}, {"#tail": "\n      ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", ", "@entity-type": "act", "#text": "subsection (a)(1)", "@value": "Protecting Consumer Access to Generic Drugs Act of 2013/s:2/ss:a/p:1", "@proposed": "true"}, {"#tail": " does not prohibit a resolution or settlement of a patent infringement claim in which the value received by the ANDA filer includes no more than\u2014", "@entity-type": "act", "#text": "subsection (a)", "@value": "Protecting Consumer Access to Generic Drugs Act of 2013/s:2/ss:a", "@proposed": "true"}], "#text": "Notwithstanding ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Exceptions"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n          ", "#text": "the right to market the drug that is to be manufactured under the ANDA involved and is the subject of the patent infringement claim, before the expiration of\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "#text": "\n          ", "@id": "H8D3ED0F65EB84CFFA4F9E5E0024F378D", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n          ", "#text": "the patent that is the basis for the patent infringement claim; or"}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "H94C9E5429A4F4C739888C6DA5EB78B1C", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "#text": "any other statutory exclusivity that would prevent the marketing of such drug; and"}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "HFF36F8E252A341D9B32B37FB423550E2", "#text": "\n            "}]}, {"#tail": "\n      ", "text": {"#tail": "\n        ", "#text": "the waiver of a patent infringement claim for damages based on prior marketing of such drug."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "H0E601617A42748779A5AA902A21DD627", "#text": "\n          "}], "#text": "\n        ", "@id": "H496F7B4723D74823AE86FAE74796E8F1", "@commented": "no"}, {"#tail": "\n      ", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall be treated as an unfair and deceptive act or practice and an unfair method of competition in or affecting interstate commerce prohibited under ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Protecting Consumer Access to Generic Drugs Act of 2013/s:2/ss:a", "@proposed": "true"}, {"#tail": " shall enforce this Act in the same manner, by the same means, and with the same jurisdiction as though all applicable terms and provisions of the ", "@entity-type": "federal-body", "#text": "Federal Trade Commission", "@entity-id": "2900"}, {"#tail": " were incorporated into and made a part of this Act.", "@entity-type": "act", "#text": "Federal Trade Commission Act", "@value": "Federal Trade Commission Act"}], "#text": "A violation of ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ". The ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 5 of the Federal Trade Commission Act", "@value": "Federal Trade Commission Act/s:5"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "15 U.S.C. 45", "@value": "usc/15/45"}, "@parsable-cite": "usc/15/45", "#text": "\n            ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Enforcement"}, "#text": "\n        ", "@id": "H2FF738E7309246E9ABD0207FE778709A"}, {"#tail": "\n    ", "text": {"#tail": "\n        ", "#text": "In this section:"}, "enum": {"#tail": "\n        ", "#text": "(d)"}, "header": {"#tail": "\n        ", "#text": "Definitions"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n        ", "term": {"#tail": " means anything that would constitute an agreement for purposes of ", "#text": "agreement"}, "#text": "The term ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 5 of the Federal Trade Commission Act", "@value": "Federal Trade Commission Act/s:5"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "15 U.S.C. 45", "@value": "usc/15/45"}, "@parsable-cite": "usc/15/45", "#text": "\n              ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "Agreement"}, "#text": "\n          ", "@id": "H41DAE27EE9F140058FCBF2CD3CF0E1CD", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "term": {"#tail": ", in reference to a patent infringement claim, includes any agreement that is contingent upon, provides a contingent condition for, or is otherwise related to the resolution or settlement of the claim.", "#text": "agreement resolving or settling"}, "#text": "The term "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Agreement resolving or settling"}, "#text": "\n          ", "@id": "H39A8876B8F7A4533B5CA0C3A45082E04", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "term": {"#tail": " means an abbreviated new drug application for the approval of a new drug under ", "#text": "ANDA"}, "#text": "The term ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505(j) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 355(j)", "@value": "usc/21/355/j"}, "@parsable-cite": "usc/21/355", "#text": "\n              ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "header": {"#tail": "\n          ", "#text": "ANDA"}, "#text": "\n          ", "@id": "H34EDDAEB2FC244ED8F770FEE4AAACEB4"}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, "term": {"#tail": " means a party that has filed an ANDA with the ", "#text": "ANDA filer"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(4)"}, "header": {"#tail": "\n          ", "#text": "ANDA filer"}, "#text": "\n          ", "@id": "H3593E705F10E40C794A25382105F43EE"}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "term": {"#tail": " means infringement of any patent or of any filed patent application, extension, reissuance, renewal, division, continuation, continuation in part, reexamination, patent term restoration, patent of addition, or extension thereof.", "#text": "patent infringement"}, "#text": "The term "}, "enum": {"#tail": "\n          ", "#text": "(5)"}, "header": {"#tail": "\n          ", "#text": "Patent infringement"}, "#text": "\n          ", "@id": "HD6FFAA9737B143E5A1BE9E2618A8B37C", "@commented": "no"}, {"#tail": "\n      ", "text": {"#tail": "\n        ", "term": {"#tail": " means any allegation made to an ANDA filer, whether or not included in a complaint filed with a court of law, that its ANDA or drug to be manufactured under such ANDA may infringe any patent.", "#text": "patent infringement claim"}, "#text": "The term "}, "enum": {"#tail": "\n          ", "#text": "(6)"}, "header": {"#tail": "\n          ", "#text": "Patent infringement claim"}, "#text": "\n          ", "@id": "HEE9A7952A0D74010993047038AE9266C", "@commented": "no"}], "#text": "\n        ", "@id": "H0192433E89774F4B91833AF1514A3C31"}], "#text": "\n      ", "@id": "HB626B4802FB9473E9037D0F4C614AC73"}, {"#tail": "\n    ", "text": {"#tail": "\n    ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may, by rule promulgated under ", "@entity-type": "federal-body", "#text": "Federal Trade Commission", "@entity-id": "2900"}, {"#tail": ", exempt certain agreements described in ", "@entity-type": "uscode", "#text": "\n          ", "external-xref": {"#tail": " of title 5, United States Code", "@parsable-cite": "usc/5/553", "#text": "section 553", "@legal-doc": "usc"}, "@value": "usc/5/553"}, {"#tail": " if the ", "@entity-type": "act", "#text": "section 2", "@value": "Protecting Consumer Access to Generic Drugs Act of 2013/s:2", "@proposed": "true"}, {"#tail": " finds such agreements to be in furtherance of market competition and for the benefit of consumers. Consistent with the authority of the ", "@entity-type": "federal-body", "#text": "Commission", "@entity-id": "2900"}, {"#tail": ", such rules may include interpretive rules and general statements of policy with respect to the practices prohibited under ", "@entity-type": "federal-body", "#text": "Commission", "@entity-id": "2900"}, {"#tail": ".", "@entity-type": "act", "#text": "section 2", "@value": "Protecting Consumer Access to Generic Drugs Act of 2013/s:2", "@proposed": "true"}], "#text": "The ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n      ", "#text": "FTC Rulemaking"}, "#text": "\n      ", "@id": "H65E494A62F3E4B9B89156689D0A09CAF"}, {"#tail": "\n    ", "text": {"{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " by inserting ", "@entity-type": "act", "#text": "subclause (V)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:D/cl:i/scl:V"}, "#tail": "\n    ", "quote": [{"#tail": " after ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " or", "@entity-type": "act", "#text": "section 2 of the Protecting Consumer Access to Generic Drugs Act of 2013", "@value": "Protecting Consumer Access to Generic Drugs Act of 2013/s:2", "@proposed": "true"}, "#text": "\n          "}, {"#tail": ".", "#text": "that the agreement has violated"}], "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended in ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 505(j)(5)(D)(i) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:D/cl:i"}, "@entity-type": "law-citation", "#text": "\n          ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n        ", "@entity-type": "uscode", "#text": "21 U.S.C. 355(j)(5)(D)(i)", "@value": "usc/21/355/j/5/D/i"}, "@parsable-cite": "usc/21/355", "#text": "\n          ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline", "#text": "\n        "}, "enum": {"#tail": "\n      ", "#text": "4."}, "header": {"#tail": "\n      ", "#text": "Forfeiture of 180-day exclusivity period under the FFDCA"}, "#text": "\n      ", "@id": "H9B0E06FCED204DB1B426978045624390"}, {"@section-type": "subsequent-section", "#tail": "\n  ", "enum": {"#tail": "\n      ", "#text": "5."}, "header": {"#tail": "\n      ", "#text": "Notice and certification of agreements"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n        ", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Section 1112(c)(2) of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:c/p:2"}, {"#tail": ")", "@entity-type": "uscode", "#text": "\n              ", "external-xref": {"#tail": " note", "@parsable-cite": "usc/21/3155", "#text": "\n            21 U.S.C. 3155\n          ", "@legal-doc": "usc"}, "@value": "usc/21/3155/note"}], "@entity-type": "law-citation", "#text": "\n            "}}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Notice of all agreements"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n        ", "quote": [{"#tail": " and inserting ", "#text": "the Commission the"}, {"#tail": "; and", "#text": "the Commission (1) the"}], "#text": "striking "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "H8A467394795E4775A65B5604779F2CBB", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n        ", "quote": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:a"}, {"#tail": "\n            ", "@entity-type": "act", "#text": "(b)", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:b"}], "#text": "; and (2) a description of the subject matter of any other agreement the parties enter into within 30 days of an entering into an agreement covered by "}, "#text": "inserting before the period at the end the following: "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "H88BC54F849664446B3463961FFC6A398", "#text": "\n          "}], "#text": "\n        ", "@id": "H5EC926CFE6AC47CEAAD1D922063B84E0"}, {"#tail": "\n    ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " is amended by adding at the end the following:", "@entity-type": "act", "#text": "Section 1112 of such Act", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112"}, "#text": "\n          "}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Certification of agreements"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n      ", "subsection": {"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:a"}, {"#tail": ", or ", "@entity-type": "act", "#text": "(b)", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:b"}, {"#tail": " shall execute and file with the ", "@entity-type": "act", "#text": "(c)", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:c"}, {"#tail": " and the ", "@entity-parent-id": "1501", "@entity-type": "federal-body", "#text": "Assistant Attorney General", "@value": "Assistant Attorney General"}, {"#tail": " a certification as follows: ", "@entity-type": "federal-body", "#text": "Commission", "@entity-id": "2900"}], "#text": "The Chief Executive Officer or the company official responsible for negotiating any agreement required to be filed under ", "quote": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and the ", "@entity-type": "federal-body", "#text": "Federal Trade Commission", "@entity-id": "2900"}, {"#tail": " under ", "@entity-type": "federal-body", "#text": "Department of Justice", "@entity-id": "1500"}, {"#tail": ", with respect to the agreement referenced in this certification: (1) represent the complete, final, and exclusive agreement between the parties; (2) include any ancillary agreements that are contingent upon, provide a contingent condition for, or are otherwise related to, the referenced agreement; and (3) include written descriptions of any oral agreements, representations, commitments, or promises between the parties that are responsive to ", "@entity-type": "act", "#text": "section 1112 of subtitle B of title XI of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/t:XI/st:B/s:1112"}, {"#tail": " or ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:a"}, {"#tail": " and have not been reduced to writing.", "@entity-type": "act", "#text": "(b) of such section 1112", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:b"}], "#text": "I declare under penalty of perjury that the following is true and correct: The materials filed with the "}}, "enum": {"#tail": "\n            ", "#text": "(d)"}, "header": {"#tail": "\n            ", "#text": "Certification"}, "#text": "\n            ", "@id": "H2DECB867A03045A8A98C4D80D8664ECD"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "H7F7FA41781B44F6BA523B5A9D1E970F1"}, "#text": "\n        ", "@id": "H5F986BAC20874DB39E1A6056B072867B"}], "@display-inline": "no-display-inline", "#text": "\n      ", "@id": "H551EBCB6E8714238AD832E4AB2BEB8B1"}], "#text": "\n    ", "@id": "H85E5A878230841F5BCD5022D88D30F5C"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2013-12-11"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HR 3709 IH: Protecting Consumer Access to Generic Drugs Act of 2013"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}